Kiley Juergens Wealth Management LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

Kiley Juergens Wealth Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,481 shares of the company’s stock after selling 2,605 shares during the quarter. Johnson & Johnson comprises 1.0% of Kiley Juergens Wealth Management LLC’s holdings, making the stock its 25th largest position. Kiley Juergens Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,082,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $40,000. WFA Asset Management Corp increased its stake in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $44,000. Disciplined Equity Management Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $45,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in shares of Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective for the company. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $145.69 on Friday. The stock has a 50-day simple moving average of $147.96 and a 200-day simple moving average of $153.85. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The stock has a market capitalization of $350.63 billion, a PE ratio of 9.08, a PEG ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the previous year, the business posted $2.68 EPS. The firm’s revenue was up 2.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. The ex-dividend date was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.40%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.